ArticleAnnals of the American Thoracic Society2020
Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19.
Open access · greenAbstract readClinical Trial Protocol
In one paragraph
Article in Annals of the American Thoracic Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Developing a Bayesian hierarchical model for a prospective individual patient data meta-analysis with continuous monitoring.BMC medical research methodology · 2023Pooled it
- Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients.Indian journal of pharmacologyPooled it
- Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19.Frontiers in cellular and infection microbiology · 2022Trial
- Trial
- A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19.Vaccines · 2023Review
- Bayesian adaptive clinical trial designs for respiratory medicine.Respirology (Carlton, Vic.) · 2022Review
- Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19.The Lancet. Respiratory medicine · 2022Review
- Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance.Journal of clinical pharmacology · 2022Article
- Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2022Review
- Learning in times of stress: Lessons from COVID-19 that will last throughout this century.European journal of internal medicine · 2022Article
- Liver Fibrosis Scores and Clinical Outcomes in Patients With COVID-19.Frontiers in medicine · 2022Article
- Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Forty-fifth ASPEN Presidential Address: Research in a pandemic-Why, what, how?JPEN. Journal of parenteral and enteral nutrition · 2021Article
- Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment.Best practice & research. Clinical anaesthesiology · 2021Review
- Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape.Clinical trials (London, England) · 2021Article
- Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs.International journal of antimicrobial agents · 2021Review
- Will Evidence-based Medicine Survive the COVID-19 Pandemic?Annals of the American Thoracic Society · 2020Article
- Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements.Frontiers in pharmacology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
33 authors at 19 institutions in 1 country.
Jonathan D CaseyDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine.ORCID 0000-0002-0977-290X
Nicholas J JohnsonDepartment of Emergency Medicine.ORCID 0000-0001-9915-0591
Matthew W SemlerDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine.ORCID 0000-0002-7664-8263
Sean P CollinsDepartment of Emergency Medicine, and.
Neil R AggarwalDivision of Lung Diseases, National Heart, Lung and Blood Institute, Bethesda, Maryland.
Roy G BrowerCritical Care Medicine, Johns Hopkins University, Baltimore, Maryland.
Steven Y ChangDivision of Pulmonary and Critical Care Medicine, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California.
John EppensteinerDepartment of Surgery, Duke University, Durham, North Carolina.
Michael FilbinDepartment of Emergency Medicine.
Kevin W GibbsSection of Pulmonary, Critical Care, Allergy and Immunologic Disease, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Adit A GindeDepartment of Emergency Medicine and.
Michelle N GongDivision of Epidemiology and Population Health, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York City, New York.
Frank HarrellDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Douglas L HaydenDepartment of Medicine, and.
Catherine L HoughDivision of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, and.
Akram KhanDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Science University School of Medicine, Portland, Oregon.
Lindsay M LeitherDivision of Pulmonary and Critical Care Medicine, Intermountain Medical Center and University of Utah, Salt Lake City, Utah.
Marc MossDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Cathryn F OldmixonDepartment of Medicine, and.
Pauline K ParkDepartment of Surgery, University of Michigan, Ann Arbor, Michigan.
Lora A ReineckDivision of Lung Diseases, National Heart, Lung and Blood Institute, Bethesda, Maryland.
Nancy J RingwoodDepartment of Medicine, and.
Bryce R H RobinsonDepartment of Surgery, University of Washington, Seattle, Washington.
David A SchoenfeldDepartment of Medicine, and.
Nathan I ShapiroDepartment of Emergency Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Jay S SteingrubDepartment of Medicine, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts.
Donna K TorrDepartment of Pharmacy Services, Vanderbilt University Medical Center, Nashville, Tennessee; and.
Alexandra WeissmanDepartment of Emergency Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Christopher J LindsellDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Todd W RiceDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine.
B Taylor ThompsonDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Samuel M BrownDivision of Pulmonary and Critical Care Medicine, Intermountain Medical Center and University of Utah, Salt Lake City, Utah.ORCID 0000-0003-1206-6261
Wesley H SelfDepartment of Emergency Medicine, and.
Pulmonary and Allergy Associates · USHarborview Medical Center · USNational Heart Lung and Blood Institute · USUniversity of Utah · USVanderbilt University · USAlbert Einstein College of Medicine · USBaystate Medical Center · USBeth Israel Deaconess Medical Center · USDuke University · USJohns Hopkins University · USMassachusetts General Hospital · USOregon Health & Science University · USUniversity of California, Los Angeles · USUniversity of Colorado Denver · USUniversity of Michigan · USUniversity of Pittsburgh · USUniversity of Washington · USVanderbilt University Medical Center · USWake Forest University · US
Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MCCC for NHLBI Prevention and Early Treatment of Acute Lung Injury PETAL NetworkU01HL123009 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI FOULKES, ANDREA S, THOMPSON, BOYD TAYLOR · 2014 to 2021
$67.2MClinical and Translational Training Program in Pulmonary MedicineT32HL087738 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lorraine B Ware · 2007 to 2026
$7.0MClinical Centers (CC) for the NHLBI Prevention and Early Treatment of Acute LungU01HL123022 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SHAPIRO, NATHAN I, TALMOR, DANIEL STUART · 2014 to 2020
$2.9MPrevention and Early Treatment of Acute Lung InjuryU01HL123004 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHAY, MICHAEL A. · 2014 to 2020
$2.6MClinical Centers (CC) for the NHLBI Prevention and Early Treatment of Acute LungU01HL123031 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HYZY, ROBERT C, PARK, PAULINE K · 2014 to 2020
$2.6MEnhancing the Surrogate Informed Consent Process for Critical Care ResearchU01HL123010 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI GINDE, ADIT A., MOSS, MARC · 2014 to 2020
$2.6MPrevention and Early Treatment of Acute Lung Injury Clinical Trials NetworkU01HL123033 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICE, TODD W · 2014 to 2020
$2.4MPreventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh - SupplementU01HL123020 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANGUS, DEREK C, YEALY, DONALD M · 2014 to 2020
$2.4MLong Term Outcomes and Macrophage Biology in Patients with EVALIU01HL123018 · NHLBI · IHC HEALTH SERVICES, INC. · PI BLEDSOE, JOSEPH R, BROWN, SAMUEL MORRIS · 2014 to 2020
$2.4MPacific Northwest Clinical Center for the NHLBI PETAL NetworkU01HL123008 · NHLBI · UNIVERSITY OF WASHINGTON · PI HOUGH, CATHERINE LEE, ROBINSON, BRYCE · 2014 to 2020
$2.3MAcute Lung Injury Group New England Program to Support PETAL Network ResearchU01HL122989 · NHLBI · BAYSTATE MEDICAL CENTER, INC. · PI STEINGRUB, JAY S · 2014 to 2020
$2.2MNCATS NIH HHS UL1 TR002243NHLBI NIH HHS K12 HL133117NHLBI NIH HHS K23 HL143053NHLBI NIH HHS K23 HL153584NHLBI NIH HHS R01 HL144624NHLBI NIH HHS T32 HL087738NHLBI NIH HHS U01 HL122989NHLBI NIH HHS U01 HL122998NHLBI NIH HHS U01 HL123004NHLBI NIH HHS U01 HL123008NHLBI NIH HHS U01 HL123009NHLBI NIH HHS U01 HL123010NHLBI NIH HHS U01 HL123018NHLBI NIH HHS U01 HL123020NHLBI NIH HHS U01 HL123022NHLBI NIH HHS U01 HL123023NHLBI NIH HHS U01 HL123027NHLBI NIH HHS U01 HL123031NHLBI NIH HHS U01 HL123033
Abstract
The ORCHID (Outcomes Related to COVID-19 treated with Hydroxychloroquine among In-patients with symptomatic Disease) trial is a multicenter, blinded, randomized trial of hydroxychloroquine versus placebo for the treatment of adults hospitalized with coronavirus disease (COVID-19). This document provides the rationale and background for the trial and highlights key design features. We discuss five novel challenges to the design and conduct of a large, multicenter, randomized trial during a pandemic, including
Indexed as
BetacoronavirusPandemicsAdultAntimalarialsCoronavirus InfectionsCOVID-19Dose-Response Relationship, DrugHospitalizationHumansHydroxychloroquineMulticenter Studies as TopicPneumonia, ViralRandomized Controlled Trials as TopicSARS-CoV-2Single-Blind MethodTreatment OutcomeAntimalarialsHydroxychloroquineARDSCOVID-19hydroxychloroquineORCHIDSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.